Literature DB >> 20065080

T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Mirjam H M Heemskerk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20065080      PMCID： PMC2805754          DOI： 10.3324/haematol.2009.016022

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

1.  Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.

Authors:  Lars T van der Veken; Miriam Coccoris; Erwin Swart; J H Frederik Falkenburg; Ton N Schumacher; Mirjam H M Heemskerk
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

Review 2.  Preclinical development of T cell receptor gene therapy.

Authors:  Gavin M Bendle; John B A G Haanen; Ton N M Schumacher
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

3.  Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Authors:  Jürgen Kuball; Michelle L Dossett; Matthias Wolfl; William Y Ho; Ralf-Holger Voss; Carla Fowler; Philip D Greenberg
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

4.  Resistance of mature T cells to oncogene transformation.

Authors:  Sebastian Newrzela; Kerstin Cornils; Zhixiong Li; Christopher Baum; Martijn H Brugman; Marianne Hartmann; Johann Meyer; Sylvia Hartmann; Martin-Leo Hansmann; Boris Fehse; Dorothee von Laer
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

5.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

6.  Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.

Authors:  Ralf-Holger Voss; Ralph A Willemsen; Jürgen Kuball; Margarete Grabowski; Renate Engel; Ratna S Intan; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

7.  Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.

Authors:  Marleen M van Loenen; Renate S Hagedoorn; Michel G D Kester; Manja Hoogeboom; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

8.  Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.

Authors:  Zsolt Sebestyén; Erik Schooten; Tamara Sals; Irene Zaldivar; Esther San José; Balbino Alarcón; Sara Bobisse; Antonio Rosato; János Szöllosi; Jan Willem Gratama; Ralph A Willemsen; Reno Debets
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

9.  Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.

Authors:  Marieke Griffioen; Esther H M van Egmond; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

10.  Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation.

Authors:  William R Burns; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Blood       Date:  2009-07-09       Impact factor: 22.113
View more
  8 in total

1.  Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML.

Authors:  Xianfeng Zha; Shaohua Chen; Lijian Yang; Li Shi; Bo Li; Xiuli Wu; Yuhong Lu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2012-10-11       Impact factor: 3.311

2.  Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer.

Authors:  Qingsong Yin; Xianfeng Zha; Lijian Yang; Shaohua Chen; Yubing Zhou; Xiuli Wu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2011-01-11       Impact factor: 17.388

3.  Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer.

Authors:  Daichi Shigemizu; Zhenjun Hu; Jui-Hung Hung; Chia-Ling Huang; Yajie Wang; Charles DeLisi
Journal:  PLoS Comput Biol       Date:  2012-02-09       Impact factor: 4.475

Review 4.  Clinical applications of gamma delta T cells with multivalent immunity.

Authors:  Drew C Deniger; Judy S Moyes; Laurence J N Cooper
Journal:  Front Immunol       Date:  2014-12-11       Impact factor: 7.561

5.  First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?

Authors:  Francoise Baylis; Marcus McLeod
Journal:  Curr Gene Ther       Date:  2017       Impact factor: 4.391

6.  Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.

Authors:  Sabino Luzzi; Alice Giotta Lucifero; Ilaria Brambilla; Mariasole Magistrali; Mario Mosconi; Salvatore Savasta; Thomas Foiadelli
Journal:  Acta Biomed       Date:  2020-06-30

7.  Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.

Authors:  Tassilo L A Wachsmann; Anne K Wouters; Dennis F G Remst; Renate S Hagedoorn; Miranda H Meeuwsen; Eline van Diest; Jeanette Leusen; Jürgen Kuball; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Oncoimmunology       Date:  2022-02-01       Impact factor: 8.110

Review 8.  Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

Authors:  Alice Giotta Lucifero; Sabino Luzzi
Journal:  Brain Sci       Date:  2021-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.